ABSTRACT
Pyrazinamide (pyrazine-2-carboxamide) is a first-line antituberculous agent critical to the success of short-course chemotherapy of tuberculosis. It is a derivative of nicotinamide, first synthesized in 1952 and subsequently shown to possess a high degree of antituberculosis activity in man (Yeager et al., 1952). The activity of pyrazinamide is restricted to the Mycobacterium tuberculosis complex—all isolates of M. bovis are resistant. Pyrazinamide is available as a pure tablet in strengths of 150, 400, or 500 mg under multiple trade names and also as a part of fixed-drug combinations with rifampicin and isoniazid. The chemical structure of pyrazinamide is shown in Figure 125.1. Chemical structure of pyrazinamide. https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781315152110/08d8042d-9481-4a8d-8c27-9bd589f6de6b/content/fig125_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
